•  
  •  
  •  
  •  

2026-07-22 02:51:19

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  StridesPharmaScience

Stock Report

  • Strides Partners with Ascent Capital to Unlock Value in Pivot Path
  • Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz
  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • Strides Pharma Science Ltd consolidated Q2FY26 net profit climbs to Rs. 127.53 crores
  • Strides and Incepta Partner to Expand Women's Health Access with WHO-Prequalified Contraceptive
  • Strides Pharma Science Ltd consolidated Q1FY26 profit at Rs. 99.60 crores
  • Strides strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg
  • Strides acquires identified ANDAs from Nostrum Laboratories, Inc., USA
  • Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg, Expanding the Existing OTC Portfolio
  • Strides Pharma Science Ltd reports consolidated net profit of Rs. 93.23 crores in Q2 FY2025
  • OneSource receives equity commitments of INR 8,010 mn from marquee investors at a pre-money equity valuation of USD 1.65 bn
  • Strides receives USFDA approval for Fluoxetine Tabs 60 mg
  • Strides announces approval from Equity Shareholders and Secured Creditors for creation of OneSource - India's first Specialty Pharma CDMO
  • Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg
  • Strides Pharma Science Ltd gets EIR from USFDA on continued GMP status for the facility in Alathur, Chennai
  • Strides Pharma Science Ltd Q1 FY2024-25 net profit rises to Rs. 70.20 crores
  • Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg
  • Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
  • Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg
  • Strides receives USFDA approval for Pregabalin Capsules
  • Stelis Biopharma updates on receipt of consideration from Syngene
  • Strides Pharma Science Ltd provided corporate guarantee to Trinity Pharma Proprietary Ltd's borrowing
  • Stelis Biopharma announces closure of its transaction with Syngene International Ltd
  • Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025